12/12/19 11:25 AM H.R. 3
An amendment, offered by Mr. Kennedy, numbered 4 printed in Part B of House Report 116-334 to require another Senate confirmed officer with HHS to carry out the negotiation duties should the Secretary of HHS have a conflict of interest. The General Counsel of HHS would be responsible for identifying these conflicts.
12/12/19 11:24 AM H.R. 3
On agreeing to the Peters amendment; Agreed to by voice vote.
12/12/19 11:15 AM H.R. 3
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Peters amendment No. 3.
12/12/19 11:15 AM H.R. 3
An amendment, offered by Mr. Peters, numbered 3 printed in Part B of House Report 116-334 to to authorize a pilot program to develop, expand, and enhance the commercialization of biomedical products, and for other purposes.
12/12/19 11:14 AM H.R. 3
On agreeing to the Tonko amendment; Agreed to by voice vote.
12/12/19 11:03 AM H.R. 3
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Tonko amendment No. 2.
12/12/19 11:03 AM H.R. 3
An amendment, offered by Mr. Tonko, numbered 2 printed in Part B of House Report 116-334 to require CMS to create and implement a measure in the Star Ratings program evaluating Medicare Advantage and Part D plans on how well they provide access to biosimilar drugs.
12/12/19 11:02 AM H.R. 3
POSTPONED PROCEEDINGS - At the conclusion of debate on the Walden amendment the Chair put the question on adoption of the amendment and by voice vote, announced that the noes had prevailed. Mr. Walden demanded a recorded vote and the Chair postponed further proceedings until a time to be announced.
12/12/19 10:49 AM H.R. 3
DEBATE - Pursuant to the provisions of H. Res. 758, the Committee of the Whole proceeded with 10 minutes of debate on the Walden amendment No. 1.
12/12/19 10:49 AM H.R. 3
An amendment, offered by Mr. Walden, numbered 1 printed in Part B of House Report 116-334 to include provisions in the bill related to Medicare Parts B&D, drug price transparency, Medicare Part D benefit redesign, MedPAC, Medicaid, FDA, and revenue provisions.
